`Filed: January 13, 2020
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`GRÜNENTHAL GMBH,
`
`Petitioner,
`
`v.
`
`ANTECIP BIOVENTURES II LLC,
`
`Patent Owner.
`____________
`
`PGR2019-00028
`U.S. Patent No. 10,052,338
`____________
`
`PETITIONER’S FIRST AMENDED EXHIBIT LIST
`
`
`
`Exhibit
`(Ex.)
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`EXHIBIT LIST
`
`Description
`
`U.S. Patent No. 9,931,352
`
`U.S. Patent No. 10,039,774
`
`U.S. Patent No. 10,052,338
`
`Abbreviation
`
`’352 patent
`
`’774 patent
`
`’338 patent
`
`Declaration of Lawrence Poree, M.D., Ph.D.
`
`Curriculum Vitae of Lawrence Poree, M.D., Ph.D.
`
`M. Varenna, L’inquadramento clinico della sindrome
`
`Varenna 2011
`
`algodistrofica (Complex Regional Pain Syndrome di
`
`tipo I). Recenti Acquisizioni, The clinical framework
`
`of algodystrophy (Complex Regional Pain Syndrome
`
`type I). An Update, GIOT Ottobre 2011 37:227-234
`
`1007
`
`M. Muratore et al., Il neridronato nel trattamento
`
`Muratore
`
`dell’algodistrofia simpatica riflessa dell’anca:
`
`confronto in aperto con il clodronato, PROGRESSI IN
`
`REUMATOLOGIA, ABSTRACT BOOK VII CONGRESSO
`
`NAZIONALE COLLEGIO DEI REUMATOLOGI
`
`OSPEDALIERI 5(Suppl. 1):89 (April 16-18, 2004)
`
`1
`
`
`
`1008
`
`D. Gatti et al., Neridronic acid for the treatment of
`
`Gatti
`
`bone metabolic diseases, EXPERT OP. ON DRUG
`
`METABOLISM & TOXICOLOGY 5(10):1305-11 (Sept.
`
`2009)
`
`1009
`
`Harden et al., Validation of proposed diagnostic
`
`Harden
`
`criteria (the “Budapest Criteria”) for Complex
`
`Regional Pain Syndrome, PAIN 150:268–274 (2010)
`
`1010
`
`P. Drummond, Sensory Disturbances in Complex
`
`Drummond
`
`Regional Pain Syndrome: Clinical Observations,
`
`Autonomic Interactions, and Possible Mechanisms,
`
`PAIN MEDICINE 11:1257-66 (2010)
`
`Excerpt of U.S. Patent Application No. 13/894,274
`
`Excerpt of U.S. Patent Application No. 14/063,979
`
`Excerpt of U.S. Patent Application No. 14/279,229
`
`Excerpt of U.S. Patent Application No. 14/536,526
`
`
`
`Excerpt of U.S. Patent Application No. 14/967,224
`
`Excerpt of U.S. Patent Application No. 14/604,524
`
`Excerpt of U.S. Patent Application No. 15/217,773
`
`Excerpt of U.S. Patent Application No. 15/360,886
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`2
`
`
`
`1019
`
`S. Bruehl, An update on the pathophysiology of
`
`complex regional pain syndrome, ANESTHESIOLOGY
`
`11: 713-25 (2010)
`
`1020
`
`Merskey et al., CLASSIFICATION OF CHRONIC PAIN
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`(Merskey & Bogduk eds. 1994)
`
`U.S. Provisional Patent App. No. 61/646,538
`
`U.S. Provisional Patent App. No. 61/647,478
`
`U.S. Provisional Patent App. No. 61/654,383
`
`U.S. Provisional Patent App. No. 61/654,292
`
`U.S. Provisional Patent App. No. 61/655,527
`
`U.S. Provisional Patent App. No. 61/655,541
`
`U.S. Provisional Patent App. No. 61/762,225
`
`U.S. Provisional Patent App. No. 61/764,563
`
`U.S. Provisional Patent App. No. 61/767,647
`
`U.S. Provisional Patent App. No. 61/767,676
`
`A. de Castro et al., Zoledronic acid to treat complex
`
`regional pain syndrome type I in adult. Case report,
`
`REV. DOR. SÃO PAULO 12(1): 71-73 (Jan.-Mar. 2011)
`
`3
`
`
`
`1032
`
`S. Bruehl et al., External validation of IASP
`
`diagnostic criteria for Complex Regional Pain
`
`Syndrome and proposed research diagnostic criteria,
`
`PAIN 81:147-54 (1999)
`
`Excerpt of U.S. Patent Application No. 15/357,932
`
`Grünenthal GmbH v. Antecip Bioventures II,
`
`PGR2017-00008, Paper 19 (Patent Owner Response)
`
`(P.T.A.B. Oct. 2, 2017)
`
`File History of U.S. Patent No. 9,931,352
`
`File History of U.S. Patent No. 10,039,774
`
`File History of U.S. Patent No. 10,052,338
`
`GIOT website print-out
`
`Excerpts of Stedman’s Medical Dictionary, 28th ed.
`
`
`
`GIOT, Archivo, https://www.giot.it/archivio/ (last
`
`visited Jan. 8, 2020)
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`1041
`
`M. Varenna et al., Treatment of complex regional
`
`pain syndrome type I with neridronate: a
`
`randomized, double-blind, placebo-controlled
`
`study, RHEUMATOLOGY 52: 534-42 (Nov. 2012)
`
`4
`
`
`
`1042
`
`M. Varenna et al., Predictors of responsiveness to
`
`bisphosphonate treatment in patients with
`
`complex regional pain syndrome type I: A
`
`retrospective chart analysis, PAIN MED. 18: 1131-
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`38 (2016)
`
`Declaration of David E. Cannady
`
`Declaration of Corinne Militello, Esq.
`
`Declaration of Antonio Tarquini
`
`Declaration of John Galvin
`
`T. Coderre & G. Bennett, A Hypothesis for the Cause
`
`of Complex Regional Pain Syndrome-Type I (Reflex
`
`Sympathetic Dystrophy): Pain Due to Deep-Tissue
`
`Microvascular Pathology, PAIN MED. 11: 1224-38
`
`(2010)
`
`Dated: January 13, 2020
`
`By: /Daniel J. Minion/
`Daniel J. Minion
`Reg. No. 53,329
`
`5
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that copies of the PETITIONER’S FIRST
`
`AMENDED EXHIBIT LIST were served on January 13, 2020 as follows:
`
`VIA ELECTRONIC MAIL
`Brent A. Johnson (Reg. No. 51,851)
`Maschoff Brennan
`100 Spectrum Center Dr.
`Ste. 1200
`Irvine, CA 92618
`Tel: 949-202-1900
`Fax: 949-453-1104
`bjohnson@mabr.com
`
`R. Parrish Freeman (Reg. No. 42,556)
`Maschoff Brennan
`1389 Center Drive, Suite 300
`Park City, UT 84098
`Tel: 435-252-1360
`pfreeman@mabr.com
`
`Dated: January 13, 2020
`
`By:
`
`/Daniel J. Minion/
`Daniel J. Minion
`Reg. No. 53,329
`
`